PHATHOM PHARMACEUTICALS, INC.
PHAT · NASDAQ
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders.
Market Data
Price
$12.01
+0.81 (+7.23%)
Market Cap$890M
P/E Ratio—
EPS$—
52W High$18.31
52W Low$2.21
Beta0.52
Data from Finnhub · Updated May 1, 2026